{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:53:11Z","timestamp":1794243191693,"version":"4.9.0"},"reference-count":40,"publisher":"Universa BV","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Background and study aims: Glucocorticoid (GC) treatment for liver failure is controversial. This study sought to evaluate the efficacy and predictive factors of glucocorticoid therapy for hepatitis B virus-related acute-on-chronic liver failure (HBV- ACLF).\n\nPatients and methods: A total of 302 patients with HBV- ACLF were enrolled and categorized by treatment modality (GC vs. Control). Baseline characteristics, liver function, disease complications, and mortality were recorded. Univariate and multivariate analysis were used to identify predictive factors for HBV-ACLF-related mortality.\n\nResults: GC therapy significantly improved the 30- and 60-day mortality of HBV-ACLF patients (4.64% vs. 11.92%, P=0.022 and 16.56% vs. 25.83%, P=0.049 for the Control and GC groups, respectively) and GC was an independent prognostic factor for 30-day mortality (OR = 0.177, 95% CI 0.051-0.616, P = 0.007). However, enhanced survival was not associated with improved liver function. There were no significant differences in the incidence of complications (i.e., ascites, bacterial infection, encephalopathy, hepatorenal syndrome, and gastrointestinal bleeding) between the GC and Control groups (P &gt;0.05), except that fungal infection occurred with higher frequency in the GC group (P = 0.037). A significant improvement in the 30-day survival associated with GC therapy was observed among patients &lt;40 years of age, a Model for End-stage Liver Disease (MELD) score of 25-35 or a CLIF- Consortium ACLF (CLIF-C ACLF) grade 0-1 (all P &lt;0.05).\n\nConclusions: GC therapy improved the short-term (30- and 60- day) mortality of patients with HBV-ACLF. This treatment may be of particular benefit to patients who are &lt;40 years of age, have a MELD score of 25-35, or have a CLIF-C ACLF grade of 0-1. (Acta gastroenterol. belg., 2022, 85, 593-600).<\/jats:p>","DOI":"10.51821\/85.4.10728","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:03:21Z","timestamp":1672949001000},"page":"593-600","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure"],"prefix":"10.51821","volume":"85","author":[{"given":"P","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.T.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.P.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27062","published-online":{"date-parts":[[2022,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"HERNAEZ R., SOLA E., MOREAU R., GINES P. Acute-on-chronic liver failure: an update. Gut., 2017, 66(3): 541-553.","DOI":"10.1136\/gutjnl-2016-312670"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"KOC OM., VERBEEK J., KOEK GH., BIELEN R., BUSSCHOTS D., GAMIL M., et al. A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia. Acta Gastroenterol Belg., 2022, 85(1): 56-61.","DOI":"10.51821\/85.1.9160"},{"key":"ref2","unstructured":"SARIN SK., CHOUDHURY A., SHARMA MK., MAIWALL R., AI MAHTAB M., RAHMAN S., et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacifc association for the study of the liver (APASL): an update. Hepatol Int., 2019, 13(4): 353-390."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"WU T., LI J., SHAO L., XIN J., JIANG L., ZHOU Q., et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on chronic liver failure. Gut., 2018, 67(12): 2181-2191.","DOI":"10.1136\/gutjnl-2017-314641"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"MARTIN-MATEOS R., ALVAREZ-MON M., ALBILLOS A. Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango. Front Immunol., 2019, 10: 973.","DOI":"10.3389\/fimmu.2019.00973"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"MOREAU R. The Pathogenesis of ACLF: The Inflammatory Response and Immune Function. Semin Liver Dis., 2016, 36(2): 133-140.","DOI":"10.1055\/s-0036-1583199"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"WANG G., TANAKA A., ZHAO H., JIA J., MA X., HARADA K., et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int., 2021, 15(2): 223-257.","DOI":"10.1007\/s12072-021-10170-1"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"SINGAL AK., BATALLER R., AHN J., KAMATH PS., SHAH VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol., 2018, 113(2): 175-194.","DOI":"10.1038\/ajg.2017.469"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"SARIN S., KUMAR M., LAU G., ABBAS Z., CHAN H., CHEN C., et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int., 2016, 10(1): 1-98.","DOI":"10.1007\/s12072-015-9675-4"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"XUE R., MENG Q. The Management of Glucocorticoid Therapy in Liver Failure. Front Immunol., 2019, 10: 2490.","DOI":"10.3389\/fimmu.2019.02490"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"GARCIA-TSAO G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol., 2005, 42 Suppl(1): S85-92.","DOI":"10.1016\/j.jhep.2004.12.006"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"RIMOLA A., GARCIA-TSAO G., NAVASA, M., PIDDOCK LJ., PLANAS R., BERNARD B., et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol., 2000, 32(1): 142-153.","DOI":"10.1016\/s0168-8278(00)80201-9"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"DE PAUW B., WALSH TJ., DONNELLY JP., STEVENS DA., EDWARDS JE., CALANDRA T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis., 2008, 46(12): 1813-1821.","DOI":"10.1086\/588660"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"BLEI AT., CORDOBA J. Hepatic encephalopathy. Am J Gastroenterol., 2001, 96(7): 1968-1976.","DOI":"10.1111\/j.1572-0241.2001.03964.x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"ARROYO V., GINES P., GERBES AL., DUDLEY FJ., GENTILINI P., LAFFI G., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology., 1996, 23(1): 164-176.","DOI":"10.1002\/hep.510230122"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"FORMAN LM., LUCEY MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Hepatology., 2001, 33(2): 473-475.","DOI":"10.1053\/jhep.2001.22481"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"JALAN R., SALIBA F., PAVESI M., AMOROS A., MOREAU R., GINES P., et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol., 2014, 61(5): 1038- 1047.","DOI":"10.1016\/j.jhep.2014.06.012"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"CHALASANI N., MADDUR H., RUSSO M., WONG R., REDDY K. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol., 2021, 116(5): 878-898.","DOI":"10.14309\/ajg.0000000000001259"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"PAPE S., SCHRAMM C., GEVERS TJUEGJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J., 2019, 7(9): 1156-1163.","DOI":"10.1177\/2050640619872408"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"ZHAO RH., SHI Y., ZHAO H., WU W., SHENG JF. Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert Rev Gastroenterol Hepatol., 2018, 12(4): 341-350.","DOI":"10.1080\/17474124.2018.1426459"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"ZHAO J., ZHANG JY., YU HW., HE YL., ZHAO JJ., Li J., et al. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell Mol Immunol., 2012, 9(5): 417-422.","DOI":"10.1038\/cmi.2011.51"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"ZHANG XQ., JIANG L., YOU JP., LIU YY., PENG J., ZHANG HY., et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res., 2011, 41(1): 46-53.","DOI":"10.1111\/j.1872-034x.2010.00740.x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"CHEN F., SHI Y., LIU X., LEI L., XU J. Corticosteroid improves liver function but does not curb the clinical progression of hepatitis B virus-related acute-on-chronic pre-liver failure. Expert Rev Gastroenterol Hepatol., 2019, 13(11):1129-1135.","DOI":"10.1080\/17474124.2019.1688143"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"CHEN JF., WANG KW., ZHANG SQ., LEI ZY., XIE JQ., ZHU JY., et al. Dexamethasone in outcome of patients with hepatitis B virus-related acute-on-chronic liver failure. J Gastroenterol Hepatol., 2014, 29(4): 800-806.","DOI":"10.1111\/jgh.12454"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"JIA L., XUE R., ZHU Y., ZHAO J., LI J., HE W., et al. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. BMC Med., 2020, 18(1): 383.","DOI":"10.1186\/s12916-020-01814-4"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"DEJAGER L., VANDEVYVER S., PETTA I., LIBERT C. Dominance of the strongest: inflammatory cytokines versus glucocorticoids. Cytokine Growth Factor Rev., 2014, 25(1):21-33.","DOI":"10.1016\/j.cytogfr.2013.12.006"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"MA T., HU T., HUNG C., WANG J., LU S., CHEN C. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One., 2019, 14(10): e0222221.","DOI":"10.1371\/journal.pone.0222221"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"OAKLEY R., CIDLOWSKI J. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol., 2013, 132(5): 1033-1044.","DOI":"10.1016\/j.jaci.2013.09.007"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"PUENGEL T., TACKE F. Repair macrophages in acute liver failure. Gut., 2018, 67(2): 202-203.","DOI":"10.1136\/gutjnl-2017-314245"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"YAN Z., TAN W., ZHAO W., DAN Y., WANG X., MAO Q., et al. Regulatory polymorphisms in the IL-10 gene promoter and HBV-related acute liver failure in the Chinese population. J Viral Hepat., 2009, 16(11): 775-783.","DOI":"10.1111\/j.1365-2893.2009.01139.x"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"IQBAL M., GIBB W., MATTHEWS SG. Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology., 2011, 152(3): 1067-1079.","DOI":"10.1210\/en.2010-1227"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"FOUCAUD-VIGNAULT M., SOAYFANE Z., MENEZ C., BERTRAND- MICHEL J., MARTIN P., GUILLOU H., et al. P-glycoprotein dysfunction contributes to hepatic steatosis and obesity in mice. PLoS One., 2011, 6(9): e23614.","DOI":"10.1371\/journal.pone.0023614"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"ZHAO B., XIE GJ., LI RF., CHEN Q., ZHANG XQ. Dexamethasone protects normal human liver cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand by upregulating the expression of P-glycoproteins. Mol Med Report., 2015, 12(6): 8093-8100.","DOI":"10.3892\/mmr.2015.4458"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"BERNSMEIER C., SINGANAYAGAM A., PATEL VC., WENDON J., ANTONIADES CG. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. Immunotherapy., 2015, 7(6): 641-654.","DOI":"10.2217\/imt.15.27"},{"key":"ref34","unstructured":"DU W., PAN XP., Li LJ. Prognostic models for acute liver failure. Hepatobiliary Pancreat Dis Int., 2010, 9(2): 122-128."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"HUANG C., YU K., ZHENG J., LI NING. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: A 10-year cohort study in a university hospital in East China. J Dig Dis., 2019, 20(1): 38-44.","DOI":"10.1111\/1751-2980.12691"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"MA K., GUO W., HAN M., CHEN G., CHEN T., WU Z., et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatol Int., 2012, 6(4): 735-743.","DOI":"10.1007\/s12072-012-9344-9"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"XU Y., JIANG Y., LI Y. Outcomes of glucocorticoid treatment in HBV- associated acute-on-chronic liver failure patients: A retrospective observational study. Turk J Gastroenterol., 2021, 32(5): 473-480.","DOI":"10.5152\/tjg.2021.20257"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"ZHAO B., ZHANG H., XIE G., LIU H., CHEN Q., LI R., et al. Evaluation of the efficacy of steroid therapy on acute liver failure. Exp Ther Med., 2016, 12(5): 3121-3129.","DOI":"10.3892\/etm.2016.3720"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"MEDIZABAL M., MARCIANO S., VIDELA MG., ANDERS M., ZEREGA A., BALDERRAMO DC., et al. Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur J Gastroenterol Hepatol., 2015, 27(6): 644-648.","DOI":"10.1097\/meg.0000000000000353"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:04:37Z","timestamp":1672949077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2057\/Efficacy%20and%20predictive%20factors%20of%20glucocorticoid%20therapy%20for%20patients%20with%20hepatitis%20B%20virus-related%20acute-on-chronic%20liver%20failure\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,6,21]]}},"URL":"https:\/\/doi.org\/10.51821\/85.4.10728","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}